Sequential anticancer therapy in a patient with metachronous primary uterine cancer and breast cancer
-
Published:2021-07-07
Issue:4
Volume:10
Page:38-46
-
ISSN:2587-6813
-
Container-title:Malignant tumours
-
language:
-
Short-container-title:Malignant Tumours
Author:
Sultanbaev A. V.1,
Nasretdinov A. F.1,
Sultanbaeva N. I.1,
Menshikov K. V.2,
Musin Sh. I.1,
Izmailov A. A.2,
Lipatov O. N.3,
Pushkarev V. A.1,
Valiakhmedov R. B.1,
Pushkarev A. V.1,
Mufazalov F. F.2
Affiliation:
1. Republican Clinical Oncological Dispensary
2. Republican Clinical Oncological Dispensary;
Bashkir state medical university
3. Bashkir state medical university
Abstract
Breast cancer (BC) is a heterogeneous disease characterized by the presence or absence of membrane receptor overexpression on tumor cells that correlates with the disease prognosis. Understanding of the patterns and mechanisms of tumor progression gained through clinical experience of managing BC patients is important. The treatment strategy depends on the hormone receptor status of the tumor, the HER2 / neu expression, and the proliferative activity level. A clinical case of advanced luminal A breast cancer is reported, and the rationale for sequential treatment strategy is provided taking into account the clinical situation and clinical course of the disease. Adequate endocrine therapy for hormone-positive metastatic BC provides long-term tumor control like in this case, as well as a high quality of life over the entire course of sequential treatment with anticancer drugs.
Publisher
Russian Society of Clinical Oncology
Subject
General Agricultural and Biological Sciences
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献